Market Performance of Amoy Diagnostics (300685.SZ)
Amoy Diagnostics traded flat, showing no net change during the 24‑hour period ending at 10:22 AM Central Europe on Friday, 23 October 2026.
- Last traded price: CNY 19.54
- Total shares outstanding: 394.8 million
- Market capitalization: CNY 7.2 billion
- Volume in last 24 hours: CNY 144.5 million
The share price has declined 13.8 % since the end of the previous month.
- 200‑day simple moving average: CNY 18.18
- 52‑week high: CNY 24.13 (14 November 2025)
- 52‑week low: CNY 15.62 (29 June 2026)
Recent Financial Update
Amoy Diagnostics Co., Ltd. released its third‑quarter 2026 results.
- Revenue growth: modest increase.
- Net profit: slight decline.
- Operating cash flow: higher, indicating stronger cash generation.
- Earnings per share (adjusted for currency impacts): improved.
- Net profit (adjusted): better than the prior period.
The company also announced a share‑transfer agreement with a major investor, reflecting ongoing adjustments to its ownership structure. Overall, the financial performance is stable, with foreign‑exchange movements presenting some pressure.
Peer Performance (Last 24 Hours)
| Symbol | Trade Move | Current Price | Market Cap | P/E (where available) |
|---|---|---|---|---|
| Genscript Biotech (1548.HK) | –4.2 % | HKD 31.58 | HKD 10 bn | – |
| Rianlon (300596.SZ) | 0 % | CNY 37.01 | CNY 8.6 bn | 15.21 |
| Chongqing Genrix Biopharma (688443.SS) | 0 % | CNY 24.14 | CNY 8.6 bn | – |
| Zhejiang Yiming Food Lt (605179.SS) | 0 % | CNY 20.16 | CNY 8.6 bn | 161.03 |
| Ningbo Kbe Electrical Tech (300863.SZ) | 0 % | CNY 32.13 | CNY 8.5 bn | 91.2 |
Company Overview
Amoy Diagnostics Co., Ltd. is headquartered in Xiamen, China, and specializes in molecular diagnostic products and services for cancer patients. Its portfolio includes gene mutation, nucleic acid extraction, and diagnostic kits for EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1. The ROS1 kit serves as a companion diagnostic for Pfizer’s crizotinib trials in China, Japan, and Korea. The company partners with AstraZeneca, Boehringer‑Ingelheim, Pfizer, Merck, and Illumina. Further information is available on the company’s website at www.amoydiagnostics.com .